Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Frontiers Media SA full text link Frontiers Media SA Free PMC article
Full text links

Actions

Share

.2019 Feb 19:10:99.
doi: 10.3389/fphar.2019.00099. eCollection 2019.

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders

Affiliations

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders

Stacey L Aldrich et al. Front Pharmacol..

Abstract

In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders. However, pharmacogenetic studies examining CYP2C19 metabolizer status and es/citalopram treatment outcomes have largely focused on adults. We report a retrospective study of electronic medical record data from 263 youth < 19 years of age with anxiety and/or depressive disorders prescribed escitalopram or citalopram who underwent routine clinicalCYP2C19 genotyping. Slower CYP2C19 metabolizers experienced more untoward effects than faster metabolizers (p = 0.015), including activation symptoms (p = 0.029) and had more rapid weight gain (p = 0.018). A larger proportion of slower metabolizers discontinued treatment with es/citalopram than normal metabolizers (p = 0.007). Meanwhile, faster metabolizers responded more quickly to es/citalopram (p = 0.005) and trended toward less time spent in subsequent hospitalizations (p = 0.06). These results highlight a disparity in treatment outcomes with es/citalopram treatment in youth with anxiety and/or depressive disorders when standardized dosing strategies were used without consideration of CYP2C19 metabolizer status. Larger, prospective trials are warranted to assess whether tailored dosing of es/citalopram based on CYP2C19 metabolizer status improves treatment outcomes in this patient population.

Keywords: CYP2C19; SSRI (selective serotonin reuptake inhibitor); antidepressant; anxiety disorders; citalopram; depressive disorder; escitalopram; pharmacogenetics.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
(A) Total number of side effects experienced during treatment with escitalopram or citalopram (es/citalopram) by 248 patients included in the tolerability analysis. CYP2C19 metabolizer status is associated with the total number of side effects experienced (p = 0.015). The association with CYP2C19 metabolizer status remained significant (p = 0.019) in a multivariate regression model that accounted for es/citalopram dose and concomitant medications. Mean and standard deviation are indicated by the bar and whiskers.(B) Discontinuation rates by CYP2C19 metabolizer status in the tolerability analysis with a documented reason for discontinuation of es/citalopram in the electronic medical record. PMs and IMs were significantly more likely to discontinue es/citalopram relative to NMs (p = 0.007, χ2), while RMs and UMs were not (p = 0.20, χ2). PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer;n, number.
FIGURE 2
FIGURE 2
(A) Cumulative days in the inpatient psychiatric unit (over the entire follow-up period after the initial hospitalization) correlated with the total number of side effects in a linear model (regression line in blackp = 2 × 10-10).(B) Cumulative days patients were admitted to the inpatient psychiatric unit during treatment with es/citalopram after the initial hospitalization by CYP2C19 metabolizer status,p = 0.076. Mean and standard deviation are indicated by the bar and whiskers. PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer;n, number.
FIGURE 3
FIGURE 3
(A) Time to first weight gain concern during es/citalopram treatment is associated with CYP2C19 metabolizer status (p = 0.018, log-rank test for trend).B, Number of activation side effects during es/citalopram treatment is associated with CYP2C19 metabolizer status (p = 0.029, one-way ANOVA with test for trend). Median and interquartile range are indicated by the bar and whiskers. PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer;n, number.
FIGURE 4
FIGURE 4
(A) Percentages of patients in the response analysis who achieved or did not achieve a response while prescribed es/citalopram (p = 0.12, χ2).(B) Time to response was associated with CYP2C19 metabolizer status (p = 0.005, log-rank test for trend).(C) Time to response dose among patients who achieved a response was not different by CYP2C19 metabolizer status (p = 0.27, log-rank test for trend).(D) Response dose was not associated with CYP2C19 metabolizer status (p = 0.67, one-way ANOVA with test for trend). Mean and standard deviation are indicated by the bar and whiskers. PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer;n, number.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Altar C. A., Hornberger J., Shewade A., Cruz V., Garrison J., Mrazek D. (2013). Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int. Rev. Psychiatry 25 509–533. 10.3109/09540261.2013.825579 - DOI - PubMed
    1. Bardach N. S., Coker T. R., Zima B. T., Murphy J. M., Knapp P., Richardson L. P., et al. (2014). Common and costly hospitalizations for pediatric mental health disorders. Pediatrics 133 602–609. 10.1542/peds.2013-3165 - DOI - PMC - PubMed
    1. Baumgartner J. L., Emslie G. J., Crismon M. L. (2002). Citalopram in children and adolescents with depression or anxiety. Ann. Pharmacother. 36 1692–1697. 10.1345/aph.1C078 - DOI - PubMed
    1. Bishop J. R., Najjar F., Rubin L. H., Guter S. J., Owley T., Mosconi M. W., et al. (2015). Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet. Genomics 25 548–554. 10.1097/FPC.0000000000000173 - DOI - PMC - PubMed
    1. Bussing R., Murphy T. K., Storch E. A., McNamara J. P., Reid A. M., Garvan C. W., et al. (2013). Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD. Psychiatry Res. 205 253–261. 10.1016/j.psychres.2012.09.019 - DOI - PMC - PubMed

LinkOut - more resources

Full text links
Frontiers Media SA full text link Frontiers Media SA Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp